Product Sales

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Product Sales

Product Sales

Net product sales consist of the following:

(In millions)	Year Ended December 31,
Net Product Sales in the United States	2021			2020			2019
EYLEA®	$	5,792.3		$	4,947.2		$	4,644.2
Libtayo®	306.3			270.7			175.7
Praluent®	170.0			150.9		*	*
REGEN-COV***	5,828.0			185.7			—
Evkeeza®	18.4			—			—
ARCALYST®	2.2		**	13.1			14.5
	$	12,117.2		$	5,567.6		$	4,834.4
* Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.
** Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.
*** Net product sales of REGEN-COV in the United States relate to product sold in connection with our agreements with the U.S. government. See Note 3 for further details.

As of December 31, 2021 and 2020, the Company had $5.059 billion and $3.112 billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.

The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for each of the years ended December 31, 2021, 2020, and 2019. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:

	Year Ended December 31,
	2021		2020		2019
Besse Medical, a subsidiary of AmerisourceBergen Corporation	30	%	51	%	57	%
McKesson Corporation	18	%	32	%	33	%
U.S. government	43	%	*		—
* Sales to the U.S. government represented less than 10% of total gross product revenue during the period

Revenue from product sales is recorded net of applicable provisions for rebates, chargebacks, and discounts, distribution-related fees, and other sales-related deductions. Accruals for chargebacks and discounts are recorded as a direct reduction to accounts receivable. Accruals for rebates, distribution-related fees, and other sales-related deductions are recorded within accrued liabilities. The following table summarizes the provisions, and credits/payments, for sales-related deductions.

(In millions)	Rebates, Chargebacks, and Discounts		Distribution- Related Fees		Other Sales- Related Deductions		Total
Balance as of December 31, 2018	$	41.1	$	42.0	$	8.3	$	91.4
Provisions	423.2		242.9		61.8		727.9
Credits/payments	(384.0)		(238.5)		(40.7)		(663.2)
Balance as of December 31, 2019	80.3		46.4		29.4		156.1
Provisions	762.9		279.9		94.1		1,136.9
Credits/payments	(641.0)		(249.1)		(78.7)		(968.8)
Balance as of December 31, 2020	202.2		77.2		44.8		324.2
Provisions	1,047.1		363.6		150.4		1,561.1
Credits/payments	(1,034.7)		(360.8)		(127.6)		(1,523.1)
Balance as of December 31, 2021	$	214.6	$	80.0	$	67.6	$	362.2